全文获取类型
收费全文 | 18422篇 |
免费 | 2468篇 |
国内免费 | 174篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 290篇 |
妇产科学 | 265篇 |
基础医学 | 936篇 |
口腔科学 | 517篇 |
临床医学 | 5765篇 |
内科学 | 1333篇 |
皮肤病学 | 111篇 |
神经病学 | 644篇 |
特种医学 | 291篇 |
外科学 | 2357篇 |
综合类 | 2323篇 |
预防医学 | 3879篇 |
眼科学 | 104篇 |
药学 | 1250篇 |
131篇 | |
中国医学 | 419篇 |
肿瘤学 | 385篇 |
出版年
2024年 | 36篇 |
2023年 | 413篇 |
2022年 | 583篇 |
2021年 | 1065篇 |
2020年 | 1126篇 |
2019年 | 1087篇 |
2018年 | 1010篇 |
2017年 | 961篇 |
2016年 | 1015篇 |
2015年 | 876篇 |
2014年 | 1336篇 |
2013年 | 1849篇 |
2012年 | 996篇 |
2011年 | 1063篇 |
2010年 | 840篇 |
2009年 | 915篇 |
2008年 | 892篇 |
2007年 | 874篇 |
2006年 | 691篇 |
2005年 | 596篇 |
2004年 | 479篇 |
2003年 | 356篇 |
2002年 | 302篇 |
2001年 | 274篇 |
2000年 | 277篇 |
1999年 | 202篇 |
1998年 | 179篇 |
1997年 | 158篇 |
1996年 | 103篇 |
1995年 | 76篇 |
1994年 | 54篇 |
1993年 | 51篇 |
1992年 | 59篇 |
1991年 | 31篇 |
1990年 | 30篇 |
1989年 | 22篇 |
1988年 | 26篇 |
1987年 | 16篇 |
1986年 | 12篇 |
1985年 | 19篇 |
1984年 | 24篇 |
1983年 | 13篇 |
1982年 | 10篇 |
1981年 | 16篇 |
1980年 | 10篇 |
1979年 | 4篇 |
1978年 | 10篇 |
1977年 | 12篇 |
1976年 | 6篇 |
1975年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
141.
Robin K. Avery Jennifer D. Motter Kyle R. Jackson Robert A. Montgomery Allan B. Massie Edward S. Kraus Kieren A. Marr Bonnie E. Lonze Nada Alachkar Mary J. Holechek Darin Ostrander Niraj Desai Madeleine M. Waldram Shmuel Shoham Seema Mehta Steinke Aruna Subramanian Janet M. Hiller Julie Langlee Sheila Young Dorry L. Segev Jacqueline M. Garonzik Wang 《American journal of transplantation》2021,21(4):1564-1575
Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/compatible (n = 260), low (0-4 plasmaphereses, n = 47), moderate (5-9, n = 74), and high (≥10, n = 94). The 1-year cumulative incidence of infection was 50.1%, 49.8%, 66.0%, and 73.5% for recipients who received none, low, moderate, and high-intensity desensitization (P < .001). The most common infections were UTI (33.5% of ILDKT vs. 21.5% compatible), opportunistic (21.9% vs. 10.8%), and bloodstream (19.1% vs. 5.4%) (P < .001). In weighted models, a trend toward increased risk was seen in low (wIRR = 0.771.402.56,P = .3) and moderately (wIRR = 0.881.352.06,P = .2) desensitized recipients, with a statistically significant 2.22-fold (wIRR = 1.332.223.72,P = .002) increased risk in highly desensitized recipients. Recipients with ≥4 infections were at higher risk of prolonged hospitalization (wIRR = 2.623.574.88, P < .001) and death-censored graft loss (wHR = 1.154.0113.95,P = .03). Post–KT infections are more common in desensitized ILDKT recipients. A subset of highly desensitized patients is at ultra-high risk for infections. Strategies should be designed to protect patients from the morbidity of recurrent infections, and to extend the survival benefit of ILDKT across the spectrum of recipients. 相似文献
142.
David P. Al-Adra Laura Hammel John Roberts E. Steve Woodle Deborah Levine Didier Mandelbrot Elizabeth Verna Jayme Locke Jonathan D'Cunha Maryjane Farr Deirdre Sawinski Piyush K. Agarwal Jennifer Plichta Sandhya Pruthi Deborah Farr Richard Carvajal John Walker Fiona Zwald Thomas Habermann Morie Gertz Philip Bierman Don S. Dizon Carrie Langstraat Talal Al-Qaoud Scott Eggener John P. Richgels George J. Chang Cristina Geltzeiler Gonzalo Sapisochin Rocco Ricciardi Alexander S. Krupnick Cassie Kennedy Nisha Mohindra David P. Foley Kymberly D. Watt 《American journal of transplantation》2021,21(2):460-474
Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy. 相似文献
143.
Christina D. Mejia Adam M. Frank Pooja Singh Anju Yadav 《American journal of transplantation》2021,21(3):1322-1325
Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies against inhibitory receptors on T cells resulting in anticancer activity. In kidney transplant (KT) recipients, ICPI use has been associated with acute allograft rejection. In failed allografts, however, the effects of ICPIs are unknown. We present a case of a 66-year-old man with a history of diabetes, renal cell cancer, left native nephrectomy, and end-stage kidney disease. He received a deceased donor KT which failed after 6 years due to biopsy-proven recurrent diabetic nephrosclerosis. He was started on hemodialysis and his immunosuppression was gradually weaned off. A year later, he was diagnosed with renal cell cancer in his right native kidney requiring nephrectomy. He later developed metastasis and was started on combination ICPIs. He developed hematuria, allograft pain, and malaise consistent with graft intolerance syndrome 28 days after starting ICPIs. Urine culture and cystoscopy were normal. A computed tomography scan of his abdomen revealed an enlarged allograft with patchy enhancement. After a multidisciplinary discussion, he underwent transplant nephrectomy. Histopathology showed chronic active T cell–mediated rejection. As ICPI use becomes prevalent, practitioners need to be aware of its potential complications among KT recipients both with functioning and failed allografts. 相似文献
144.
Stefan Schwarz Nina Rahimi Daria Kifjak Moritz Muckenhuber Martin Watzenböck Alberto Benazzo Peter Jaksch Sylvia Knapp Walter Klepetko Konrad Hoetzenecker the Vienna Lung Transplant Group 《American journal of transplantation》2021,21(6):2132-2144
Objectifying donor lung quality is difficult and currently there is no consensus. Several donor scoring systems have been proposed in recent years. They all lack large-scale external validation and widespread acceptance. A retrospective evaluation of 2201 donor lungs offered to the lung transplant program at the Medical University of Vienna between January 2010 and June 2018 was performed. Five different lung donor scores were calculated for each offer (Oto, ET, MALT, UMN-DLQI, and ODSS). Prediction of organ utilization, 1-year graft survival, and long-term outcome were analyzed for each score. 1049 organs were rejected at the initial offer (group I), 209 lungs declined after procurement (group II), and 841 lungs accepted and transplanted (group III). The Oto score was superior in predicting acceptance of the initial offer (AUC: 0.795; CI: 0.776–0.815) and actual donor utilization (AUC: 0.660; CI: 0.618–0.701). Prediction of 1-year graft survival was best using the MALT score, Oto score, and UMN-DLQI. Stratification of early outcome by MALT was significant for length of mechanical ventilation (LMV), PGD3 rates, ICU stay and hospital stay, and in-hospital-mortality, respectively. To the best of our knowledge, this study is the largest validation analysis comparing currently available donor scores. The Oto score was superior in predicting organ utilization, and MALT score and UMN-DLQI for predicting outcome after lung transplantation. 相似文献
145.
Joseph J. Alukal Talan Zhang Paul J. Thuluvath 《American journal of transplantation》2021,21(6):2211-2219
There is a paucity of data on the outcome of liver transplantation (LT) in Budd-Chiari Syndrome (BCS) patients who are listed as status 1. The objective of our study was to determine patient or graft survival following LT in status 1 BCS patients. We utilized United Network for Organ Sharing (UNOS) database to identify all adult patients (> 18 years of age) listed as status 1 with a primary diagnosis of BCS in the United States from 1998 to 2018, and analyzed their outcomes and compared it to non-status 1 BCS patients. Four hundred and forty-six patients with BCS underwent LT between 1998 and 2018, and of these 55 (12.3%) were listed as status 1. There was no difference in long-term post-liver transplant or “intention-to-treat” survival from the time of listing to death or the last day of follow-up between status 1 and non-status 1 groups. Graft and patient survival at 5 years for status 1 patients were 75% and 82%, respectively. Cox regression analysis showed that patients listed as status 1 (aHR: 0.45, p < .02) were associated with a better survival. BCS patients listed as status 1 have excellent survival following emergency LT. 相似文献
146.
Benjamin Coiffard Philipp M. Lepper Eloi Prud’Homme Florence Daviet Nadim Cassir Heinrike Wilkens Sami Hraiech Frank Langer Pascal A. Thomas Martine Reynaud-Gaubert Robert Bals Hans-Joachim Schäfers Laurent Papazian Frederik Seiler 《American journal of transplantation》2021,21(4):1586-1596
It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 questions, both regarding the management of a LTx program in the COVID-19 era and the therapeutic strategies to treat COVID-19 LTx recipients. We received a total of 78 responses from 15 countries. Among participants, 81% declared a reduction of the activity and 47% restricted LTx for urgent cases only. Sixteen centers observed deaths on waiting listed patients and eight centers performed LTx for COVID-19 disease. In 62% of the centers, COVID-19 was diagnosed in LTx recipients, most of them not severe cases. The most common immunosuppressive management included a decreased dose or pausing of the cell cycle inhibitors. Remdesivir, hydroxychloroquine, and azithromycin were the most proposed antiviral strategies. Most of the centers have been affected by the COVID-19 pandemic and proposed an active therapeutic strategy to treat LTx recipients with COVID-19. 相似文献
147.
Hanno Niess Nikolaus Börner Maximilian Muenchhoff Elham Khatamzas Manfred Stangl Alex Graf Philipp Girl Enrico Georgi Dionysios Koliogiannis Gerald Denk Michael Irlbeck Jens Werner Markus Guba 《American journal of transplantation》2021,21(4):1629-1632
To date, little is known about the duration and effectiveness of immunity as well as possible adverse late effects after an infection with SARS-CoV-2. Thus it is unclear, when and if liver transplantation can be safely offered to patients who suffered from COVID-19. Here, we report on a successful liver transplantation shortly after convalescence from COVID-19 with subsequent partial seroreversion as well as recurrence and prolonged shedding of viral RNA. 相似文献
148.
Chris J. Callaghan Benedict L. Phillips Theodora Foukaneli Susan Robinson Christopher J. E. Watson 《American journal of transplantation》2021,21(4):1376-1381
Ex situ normothermic machine perfusion (NMP) is being used increasingly in the assessment of higher risk deceased donor organs and to facilitate prolonged organ storage. Third-party packed red blood cells (pRBCs) are often used as an oxygen carrier in the perfusate of ex situ NMP. Despite the increasing interest in NMP, comparatively little attention has been paid to the appropriate selection of pRBCs. This includes the choice of ABO blood group and Rhesus D status, the need for special requirements for selected recipients, and the necessity for traceability of blood components. Flushing organs with cold preservation solution after NMP removes the overwhelming majority of third-party allogeneic pRBCs, but residual pRBCs within the organ may have biologically relevant effects following implantation as they enter the recipient's circulation. This review considers these issues, and suggests that national transplant and blood transfusion agencies work together to develop a co-ordinated approach within each country. This is especially important given the possibility of organ re-allocation between centers after ex situ NMP, and the ongoing development of organ perfusion hubs. 相似文献
149.